5PSQ-127 Opioid withdrawal in patients with fibromyalgia

<h3>Background and Importance</h3> Fibromyalgia is a pathology with a widespread pain whose control is sometimes inadequate. This may involve the prescription of opioids, which may develop a pattern of dependence known as Opioid Use Disorder (OUD).Furthermore, clinical guidelines expose the lack of benefit of opioids in fibromyalgia, and none make recommendations in favour of their use in these cases. <h3>Aim and Objectives</h3> Carry out a procedure developed in our Public Health System to address opioid deprescription in patients with fibromyalgia and therefore with chronic non-oncological pain through creation of a multidisciplinary team. <h3>Material and Methods</h3> Descriptive study of interventions on active opioid prescriptions in patients with fibromyalgia. These lists were provided by our Health System in January 2023, with actions being carried out until September 2024. Sex, age, treatment duration, communication to the responsible Primary Care (PC) doctor were collected. A Multidisciplinary Team for Opioid Deprescription was formed: Medical Director, PC Pharmacist and Hospital Pharmacist, Addiction Treatment Centre Doctor, PC doctor, Mental Health Doctor and Pain Unit Doctor. This team developed a clinical deprescribing protocol that established that only one PC doctor would prescribe opioids to a patient, avoiding redundancies or paper prescriptions and with whom communication would be established. The interventions carried out by the PC and AH pharmacists were: Analyse the list of patients and exclude those who, due to their clinical situation (cancer, end of treatment, death), were not candidates for this intervention. Inform the responsible doctors by telephone/email so that they, after assessing the patient’s clinical situation, could begin the gradual deprescribing process. Carry out evolution periodic monitoring of these patients. <h3>Results</h3> The list contained 48 patients. Two were excluded due to death. Of the 46 patients reviewed,44 were women, with an average age of 65 years. The median duration of treatment was 28 months (1–127). During the study period,73.9% of the prescriptions (34) were communicated to prescribing physicians. 24 patients (70.1%) began a deprescribing process, two of them without prior communication from Pharmacy Service. Two patients continued with opioid treatment due to developing oncological pathology. <h3>Conclusion and Relevance</h3> To address opioid misuse by patients with fibromyalgia, there must be joint collaborative action between professionals involved, in order to achieve optimal control of chronic non-oncological pain, highlighting the work of pharmacists as a link between health professionals. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest